Loading...
Market
First region to adopt Kebilidi post-US approval by December 31, 2024?
2
Resolution / Starting Odds
Europe • 25%
Asia • 25%
South America • 25%
Other • 25%
PTC Therapeutics' announcements or regional health authority approvals
Story
FDA Approves PTC Therapeutics' Brain-Delivered Gene Therapy Kebilidi for AADC Deficiency
Nov 14, 2024, 01:23 PM
The U.S. Food and Drug Administration (FDA) has approved PTC Therapeutics' gene therapy for Aromatic L-amino acid decarboxylase (AADC) deficiency, a potentially fatal enzyme deficiency disorder. This therapy, marketed under the name Kebilidi, is the first brain-delivered gene therapy approved in the United States. The approval was granted following an open-label study involving 13 patients and the use of historical control data.
View original story
Similar markets
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Yes • 50%
No • 50%
United States • 25%
European Union • 25%
Africa • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
India • 25%
South Africa • 25%
Brazil • 25%
Other • 25%
USA • 25%
European Union • 25%
Africa • 25%
Other • 25%
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
Sub-Saharan Africa • 25%
Southeast Asia • 25%
South America • 25%
Other • 25%
United States • 25%
European Union • 25%
South Korea • 25%
Other • 25%
Canada • 25%
European Union • 25%
Japan • 25%
Other • 25%
European Union • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%